Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 07:31:32 2024-05-10 EDT 5-day change 1st Jan Change
93.79 EUR +0.65% Intraday chart for Sanofi +2.73% +4.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
SANOFI : JP Morgan reaffirms its Neutral rating ZD
Novavax Shares Surge on $1.4 Billion Vaccine Licensing Deal with Sanofi DJ
European Midday Briefing : Stocks Rise on Renewed Fed Rate-Cut Hopes DJ
Novavax Unveils Deal With Sanofi to Co-commercialize COVID-19 Vaccine, Develop Novel Medication MT
CAC40: continues its rise, close to its all-time high CF
Sanofi to Acquire Minority Stake in Novavax Under Co-exclusive Licensing Deal for COVID-19 Vaccine MT
Sanofi: co-exclusive licensing agreement with Novavax CF
France's Sanofi in COVID-19 vaccine deal with Novavax - statement RE
Royalty Pharma to Acquire Frexalimab Royalties, Milestones for $525 Million in Cash MT
Sanofi Close to Choosing BNP, BofA for Consumer Health Spinoff Deal MT
Bank of America, BNP Set to Win Lead Roles on Sanofi's Consumer-Healthcare Spin Off MT
Sector Update: Financial Stocks Higher Monday Afternoon MT
Bank of America, BNP Set to Win Lead Roles on Sanofi's Consumer-Healthcare Spin Off MT
Bank of America, BNP Set to Win Lead Roles on Sanofi's $20 Billion Consumer Healthcare Spin Off, Bloomberg Reports MT
SANOFI : Buy rating from UBS ZD
GSK plc : Back on track Our Logo
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading MT
Sanofi: new positive data for Beyfortus CF
Sanofi Announces Board and Committee Appointments CI
Sanofi Approves Ordinary Annual Dividend for the Fiscal Year 2023, Payable on May 15, 2024 CI
European Equities Traded in the US as American Depositary Receipts Decline MT
SANOFI : Jefferies reiterates its recommendation on the stock CF
SANOFI : Deutsche Bank gives a Sell rating ZD
SANOFI : JP Morgan remains Neutral ZD
Sanofi to present advances at ATS in San Diego CF
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
93.18 EUR
Average target price
108.1 EUR
Spread / Average Target
+15.97%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sector Update: Health Care Stocks Mixed Premarket Tuesday
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW